Yidu Tech has a Cash Ratio of 7.33. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Yidu Tech's Cash Ratio or its related term are showing as below:
STU:0EL'
s Cash Ratio Range Over the Past 10 Years
Min: 0.21 Med: 6.46 Max: 11.19
Current: 7.33
During the past 6 years, Yidu Tech's highest Cash Ratio was 11.19. The lowest was 0.21. And the median was 6.46.
STU:0EL's Cash Ratio is ranked better than 95.77% of 662
companies
in the Healthcare Providers & Services industry
Industry Median: 0.51
vs STU:0EL: 7.33
Yidu Tech Cash Ratio Historical Data
The historical data trend for Yidu Tech's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Yidu Tech's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yidu Tech's Cash Ratio Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yidu Tech's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Yidu Tech's Cash Ratio falls into.
Yidu Tech Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Yidu Tech's Cash Ratio for the fiscal year that ended in Mar. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yidu Tech (STU:0EL) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Yidu Tech Cash Ratio Related Terms
Thank you for viewing the detailed overview of Yidu Tech's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Yidu Tech offers healthcare Big Data. It is an AI cloud-based firm providing solutions and tools to aid in more informed decisions to drive better efficiency in clients' strategies. Its clients are hospitals, pharmaceutical, biotech and medical device firms, research institutions, insurance companies, patients, and regulators. It three business segments are: Big Data platform and solutions, which partners with hospitals and policymakers to drive better efficiency; life sciences solutions, which enables better probability of clinical trial success with less drug development time and cost; and health management solutions, which helps with patient management. The Big Data platform accounted for 33% of revenue, life science solutions 30%, and health management solutions 27%, in fiscal 2022.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:0EL has been successfully added to your 